Quantitative benefit-risk modelling of infliximab biosimilar inflectra versus reference product remicade in the treatment of Crohn's disease

被引：0
|
作者：
Catt, Heather [1 ]
Hughes, Dyfrig [2 ]
Bodger, Keith [1 ]
Kirkham, Jamie [1 ]
机构：
[1] Univ Liverpool, Liverpool, Merseyside, England
[2] Univ Bangor, Bangor, Gwynedd, Wales
来源：
TRIALS | 2017年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
P143
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis
    Battat, Robert
    Ma, Christopher
    Jairath, Vipul
    Khanna, Reena
    Feagan, Brian G.
    DRUG SAFETY, 2019, 42 (05) : 617 - 632
  • [12] Infliximab (Remicade) treatment in Crohn's disease and antinuclear antibody (ANA) formation.
    Vermeire, S
    Noman, M
    Van Assche, C
    Esters, N
    Joossens, S
    Baert, F
    D'Haens, G
    Cornillie, F
    Schaible, T
    Godefridis, L
    Bossuyt, X
    Rutgeerts, P
    GASTROENTEROLOGY, 2001, 120 (05) : A69 - A69
  • [13] Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn's disease
    Sieczkowska, J.
    Jarzebicka, D.
    Oracz, G.
    Meglicka, M.
    Dadalski, M.
    Kierkus, J.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S413 - S414
  • [14] Effectiveness and safety of reference infliximab and biosimilar in Crohn's disease: a French equivalence study
    Meyer, A.
    Rudant, J.
    Drouin, J.
    Weill, A.
    Carbonnel, F.
    Coste, J.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S49 - S49
  • [15] Outcome of pregnancy in women receiving REMICADE® (infliximab) for the treatment of Crohn's disease or rheumatoid arthritis
    Katz, JA
    Lichtenstein, GR
    Keenan, GF
    Healy, DE
    Jacobs, SJ
    GASTROENTEROLOGY, 2001, 120 (05) : A69 - A69
  • [16] Consistent treatment benefit with infliximab in patients with fistulizing Crohn's disease
    Onken, JE
    Sands, B
    Hogezand, R
    Haens, G
    Braakman, T
    DeWoody, K
    Schaible, T
    Targon, S
    Hanauer, S
    van Deventer, S
    Rutgeerts, P
    Present, D
    GASTROENTEROLOGY, 1999, 116 (04) : A788 - A788
  • [17] INFLIXIMAB VERSUS ADALIMUMAB IN THE TREATMENT OF PERIANAL CROHN'S DISEASE
    Maas, Laura A.
    Limketkai, Berkeley N.
    Lazarev, Mark
    Melia, Joanna
    Selaru, Florin M.
    Parian, Alyssa M.
    GASTROENTEROLOGY, 2022, 162 (07) : S817 - S817
  • [18] Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease
    Reinisch, Walter
    Gecse, Krisztina
    Halfvarson, Jonas
    Irving, Peter M.
    Jahnsen, Jorgen
    Peyrin-Biroulet, Laurent
    Rogler, Gerhard
    Schreiber, Stefan
    Danese, Silvio
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (01) : 106 - 122
  • [19] Outcome of pregnancy in women receiving Remicade® (infliximab) for the treatment of Crohn's disease or rheumatoid arthritis.
    Antoni, CE
    Furst, D
    Manger, B
    Lichtenstein, GR
    Keenan, GF
    Healy, DE
    Jacobs, SJ
    Katz, JA
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S152 - S152
  • [20] Benefit-risk assessment of the TNF-antagonists adalimumab and certolizumab pegol for maintenance treatment of Crohn's disease
    Colombel, Jean-Frederic
    Panaccione, Remo
    Robinson, Anne
    Thakkar, Roopal
    Huang, Bidan
    Pollack, Paul
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S22 - S23
12345